Video

Role of Venetoclax in Treatment of AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.

Related Videos
Related Content
AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML
April 27th 2025

AACR 2025: Off-the-Shelf CAR NK Therapy SENTI-202 Shows Potential for Complete Remission in R/R AML

Alana Hippensteele, Lead Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Playing by the Oncology Pharmacogenomics Rules
April 23rd 2025

Playing by the Oncology Pharmacogenomics Rules

Benjamin Gibson, PharmD, PAHM
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Acute lymphoblastic leukemia (ALL) -- Image credit: MQ-Illustrations | stock.adobe.com
April 21st 2025

A Step Forward: Optimizing the Delivery of Pegaspargase Therapy in Adult Patients With ALL

Jose Tinajero, PharmD, BCOP Sharon Xu, PharmD, BCOP
Red blood cells | Image Credit: © digitalpochi - stock.adobe.com
April 18th 2025

Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients

Alexandra Gerlach, Associate Editor